You can save this article by registering for free here. Or sign-in if you have an account.
Article content
A report quietly released last week by Public Health Ontario (PHO) tallies the number of people in the province who have presented to hospital with heart inflammation following mRNA vaccination, and it skews heavily towards young people.
Advertisement 2
Story continues below
This advertisement has not loaded yet, but your article continues below.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events.
Unlimited online access to The Province and 15 news sites with one account.
The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on.
Daily puzzles and comics, including the New York Times Crossword.
Support local journalism.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events.
Unlimited online access to The Province and 15 news sites with one account.
The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on.
Daily puzzles and comics, including the New York Times Crossword.
Support local journalism.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
Access articles from across Canada with one account.
Share your thoughts and join the conversation in the comments.
As of Aug. 7, there were 106 incidents of myocarditis/pericarditis in Ontarians under the age of 25. That’s slightly more than half of the total of all such incidents.
Broken down further, 31 of these cases were in 12- to 17-year-olds and 75 were in 18- to 24-year-olds. The vast majority — 80% — were in males.
Article content
The report explains that PHO issued a directive in June for public health units to increase their surveillance of this side effect following reports from the United States and Israel of similar concerns unfolding in those countries.
“The reporting rate of myocarditis/pericarditis was higher following the second dose of mRNA vaccine than after the first, particularly for those receiving the Moderna vaccine as the second dose of the series (regardless of the product for the first dose),” the report explains.
Canucks Report
Essential reading for hockey fans who eat, sleep, Canucks, repeat.
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Thanks for signing up!
A welcome email is on its way. If you don't see it, please check your junk folder.
The next issue of Canucks Report will soon be in your inbox.
We encountered an issue signing you up. Please try again
Article content
Advertisement 3
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
PHO adds that the reporting rate for heart inflammation in those 18-24 was seven times higher with Moderna than with Pfizer. (The only vaccine currently used for 12- to 17-year-olds in Ontario is Pfizer.)
While PHO initially worked with reports of 314 such incidents, upon further investigation they narrowed that number down to just over 200.
There have in total been 202 emergency room visits across all age groups for such issues following vaccination, with 146 leading to hospitalization. Three of these have led to ICU admission.
When it comes to older age brackets, there were 54 persons aged 25-39 included in the tally and 44 persons aged 40 and over.
When broken down by the number of overall people who have received the vaccines, the reporting rate for this side effect is 7.4 per million for Pfizer and 20 per million for Moderna.
The highlights section of the PHO report conclude with a note that “COVID-19 vaccines continue to be recommended and are highly effective at preventing symptomatic infection and severe outcomes from COVID-19 disease, which is also associated with a risk of myocarditis.”
Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information.
This website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Service and Privacy Policy.
Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information.